• Latest Posts

CellCentric receives FDA Fast Track designation for relapsed refractory multiple myeloma drug

GPCR Therapeutics launches multiple myeloma trial

Janssen looks for talquetamab marketing approval

Legend Biotech new drug application approved in China

Step Pharma announces promising pre-clinical cancer data


MIF invests in KAHR to explore lead immunotherapy drug for multiple myeloma

Oncopeptides starts European commercialization of myeloma drug in Germany

Knockback for drug to treat patients with relapsed or refractory multiple myeloma

Collaboration to explore gene therapy products for neurodegenerative disorders

Update: US District Court Rules Against MorphoSys’ Cancer Immunotherapy Patents

Genmab and Janssen Suffer Combination Therapy Setback